Targovax ASA - Special Call Transcript
Just wanted to introduce Torbjørn Furuseth, the CFO of Targovax.
¸ -
Thank you, and good afternoon, everyone. And thank you for staying through the day on a Friday afternoon. I am to represent, as [Jan] said, from Targovax. And today -- with me today also, we have Dr. Alexander Shoushtari from Memorial Sloan Kettering. Dr. Shoushtari is a melanoma expert and the principal investigator of one of our trials. So Alexander will do most of the talking today. But I just wanted to give a short introduction of Targovax first.
We are listed at the Oslo Stock Exchange in Norway, and there will be forward-looking statements. And Targovax is developing oncolytic viruses to activate the patient's immune system. And as you all know, there has been a paradigm shift in cancer therapy with the breakthrough of immunotherapy. And this shift has been led by the checkpoint inhibitors, treating and curing thousands of patients, and it's now a $20 billion market. But despite this success, only 10% to 40% of patients respond to a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
